Clinical Trials | December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Subscribe To Our Newsletter & Stay Updated
